Patient safety is our top priority. Based on the ICH guidelines, the pharmacovigilance systems of international pharmaceutical companies, and the regulatory requirements of the NMPA, Chipscreen Biosciences has created an integrated multi-division pharmacovigilance system administered by a dedicated Pharmacovigilance Department.
This department is responsible for monitoring, evaluating, and managing safety risks during the entire product life cycle, from first-in-human trials to clinical development and further to post-marketing safety assurance. To ensure drug safety, the department is also responsible for communicating with regulatory authorities and filing reports in accordance with regulatory requirements. We have also developed a series of SOPs and initiated regular training for all employees, requiring them to report any issues related to drug safety or quality promptly.
On March 1, 2015, the Chidamide (Epidaza®) charitable donation campaign was launched. By the end of December 2020, more than 40,000 boxes of medicine had been donated to more than 3,300 patients. This initiative has greatly reduced the financial burden on patients, while extending their lives and improving quality of life.
Website for the Epidaza® donation campaign：http://www.aipusha.com/charit-89.html